Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

Genome-wide characterization of dynamic DNA 5-hydroxymethylcytosine and TET2-related DNA demethylation during breast tumorigenesis

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

Genome-wide Analysis Reveals TET-and TDG-mediated 5-Methylcytosine Oxidation Dynamics

The Molecular Basis Of Dna Demethylation

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

Circulating Methylated DNA As Biomarkers for Cancer Detection

Wemics: A Single‐Base Resolution Methylation Quantification Method for Enhanced Prediction of Epigenetic Regulation

Genome-wide 5-Hydroxymethylcytosine Profiling Analysis Identifies MAP7D1 As A Novel Regulator of Lymph Node Metastasis in Breast Cancer.

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

Uncoordinated expression of DNA methylation-related enzymes in human cancer

Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?

Molecular Characterization of the Clinical and Tumor Immune Microenvironment Signature of 5-methylcytosine-Related Regulators in non-small Cell Lung Cancer

DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation

DNA methylation, its mediators and genome integrity.

Pan-cancer Analysis of DNA Epigenetic Modifications by Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry

DNA methylation profiles capturing breast cancer heterogeneity

Whole DNA Methylome Profiling in Lung Cancer Cells Before and after Epithelial-to-mesenchymal Transition.

Whole-Genome Analysis of the Methylome and Hydroxymethylome in Normal and Malignant Lung and Liver

DNA Methylation: From Cancer Biology to Clinical Perspectives

An improved method for genome wide DNA methylation profiling correlated to transcription and genomic instability in two breast cancer cell lines

The Role of DNA Methylation and DNA Methyltransferases in Cancer